Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × Leukemia, Myeloid, Acute × ivosidenib × Clear all

Status

Recruiting 11 Active not recruiting 6 Withdrawn 2 Completed 2 Not yet recruiting 1 Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

ivosidenib 1 gilteritinib 1 cc-486 1 Gemtuzumab 1 Azacitidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03245424 2018-07-24

Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

Agios Pharmaceuticals, Inc.

Approved for marketing

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡